Skip to main content

Apogee Therapeutics, Inc. (APGE) Stock

Apogee Therapeutics, Inc. Stock Details, Movements and Public Alerts

Apogee Therapeutics (APGE): The Clinical-Stage Biotech Betting Big on Next-Gen Antibody Therapies

Founded in 2022 by seasoned biotech executives and backed by top-tier VCs, Apogee Therapeutics burst onto the scene with $188M Series B funding and immediate IPO plans. Under CEO Michael Henderson's leadership, the company is advancing multiple antibody candidates targeting massive markets: atopic dermatitis ($15B+), asthma ($20B+), and chronic rhinosinusitis ($8B+). With lead candidate APG777 in Phase 2 trials showing promising safety and efficacy, Apogee has attracted unanimous bullish ratings from analysts—11 Buy/Strong Buy, zero Holds or Sells. However, with zero revenue, -$270M annual cash burn, and typical 10+ year development timelines, APGE is explicitly for aggressive biotech investors willing to stomach 50%+ volatility while awaiting binary clinical readouts.

52-Week Range

$80.99 - $26.20

-4.53% from high · +195.11% from low

Avg Daily Volume

942,409

20-day average

100-day avg: 731,693

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

-15.56

Price to Book

7.82

EV/EBITDA

-16.83

EPS (TTM)

-$4.38

Beta

1.42

Similar volatility to market

Q:How is APGE valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is APGE's risk profile compared to the market?
With a beta of 1.42, Apogee Therapeutics, Inc. is roughly as volatile as the market, moving in line with broad market trends. This moderate beta suggests the stock offers market-level returns without excessive volatility. The price-to-book ratio of 7.82 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

0.00%

EBITDA

$-282,332,000

Return on Equity

-38.41%

Return on Assets

-25.26%

Q:How profitable and efficient is APGE's business model?
Profitability metrics are not available for this stock.
Q:What are APGE's recent growth trends?
Growth data is not available for this stock.

Company Size & Market

Market Cap

$5.3B

Shares Outstanding

54.83M

Book Value/Share

$9.89

Asset Type

EQUITY

Q:What is APGE's market capitalization and position?
Apogee Therapeutics, Inc. has a market capitalization of $5.3B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 54.83M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.
Q:How does APGE's price compare to its book value?
Apogee Therapeutics, Inc.'s book value per share is $9.89, while the current stock price is $77.32, resulting in a price-to-book (P/B) ratio of 7.82. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$96.85

25.25% upside potential

Analyst Recommendations

Strong Buy

1

Buy

11

Hold

0

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for APGE?
12 analysts cover APGE with 100% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $96.85 implies 25.3% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on APGE?
Current analyst recommendations:1 Strong Buy, 11 Buy, 000The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Dec 27, 2025, 02:08 AM

Technical Indicators

RSI (14-day)

65.03

Neutral

50-Day Moving Average

$65.80

17.51% above MA-50

200-Day Moving Average

$45.61

69.52% above MA-200

MACD Line

3.56

MACD Signal

4.10

MACD Histogram

-0.53

Bearish

Q:What does APGE's RSI value tell investors?
The RSI (Relative Strength Index) for APGE is currently 65.03, indicating the stock is showing bullish momentum (60-70 range). The stock has positive momentum without being extremely overbought. This zone often occurs during healthy uptrends where buyers remain in control. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
Q:How should traders interpret APGE's MACD and moving average crossovers?
MACD analysis shows the MACD line at 3.56 below the signal line at 4.10, with histogram at -0.53. This bearish crossover indicates downward pressure. The 50-day MA ($65.80) is above the 200-day MA ($45.61), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Dec 27, 2025, 12:45 AM

Active Alerts

Alert Condition
Price decreases by
Threshold
10%
Created
Dec 3, 2025, 03:54 PM

Apogee Therapeutics (APGE) Stock Analysis 2025: Complete Investment Guide

From Stealth Launch to $3.7B Valuation

Michael Henderson didn't waste time when he co-founded Apogee Therapeutics in 2022. Within 18 months, the company raised $188M Series B, initiated clinical trials, and completed a successful IPO—uncommon speed in biotech. The aggressive timeline reflects investor confidence in Apogee's differentiated approach: developing subcutaneous antibodies that offer convenience advantages over IV infusions, target validated pathways (IL-13, IL-31, OX40L), and leverage proven mechanisms from approved drugs like Dupixent. Apogee's strategy isn't groundbreaking science—it's better engineering of existing biology combined with smart target selection in massive, underserved markets.

Pipeline: Three Shots on Goal

  • •APG777 (Anti-IL-13): Lead candidate for atopic dermatitis in Phase 2; targets same pathway as $10B+ Dupixent
  • •APG808 (Anti-IL-31RA): For prurigo nodularis and chronic pruritus; Phase 1 completed, Phase 2 expected 2025
  • •APG990 (Anti-OX40L): For asthma and CRSwNP; preclinical with IND filing planned 2025
  • •Market Opportunity: Combined addressable market exceeds $40B with multiple blockbuster drug precedents
  • •Differentiation: Subcutaneous delivery, extended dosing intervals, improved safety profiles vs. competitors

Financial Reality: Burning Cash to Reach Approval

  • •Revenue: $0 (typical for clinical-stage biotech; won't generate revenue until approval ~2027-2028)
  • •Operating Losses: -$270M EBITDA reflects clinical trial costs, manufacturing scale-up, and team expansion
  • •Cash Runway: $700M+ raised provides 2+ years of runway through critical Phase 2/3 data readouts
  • •Burn Rate: $120-150M annually; typical for 3-asset clinical-stage company with multiple trials
  • •Dilution Risk: Will need additional capital raise in 2026-2027; market reception depends on clinical progress

Growth Catalysts

  • •Phase 2 Data Readouts: APG777 results expected Q1 2026; positive data could double stock
  • •Partnership Opportunities: Big pharma often acquires/partners mid-stage assets to de-risk development
  • •Regulatory Milestones: IND filings for APG990, Phase 3 initiation for APG777 drive valuation re-rating
  • •Commercial Validation: Dupixent's $10B+ sales prove market appetite for IL-13 pathway drugs
  • •Pipeline Expansion: Additional indications (e.g., food allergies, COPD) expand addressable market

Risks & Challenges

  • •Clinical Failure: If APG777 misses endpoints, stock could lose 60%+ overnight (biotech binary risk)
  • •Competitive Crowding: 15+ companies developing IL-13 inhibitors; differentiation may not matter if efficacy similar
  • •Capital Markets Risk: If biotech IPO window closes, financing future trials becomes difficult/dilutive
  • •Timeline Slippage: Patient enrollment delays, manufacturing issues, or regulatory holds extend cash runway
  • •Total Loss Scenario: All three programs fail clinically; company liquidates; shareholders lose 100%

Competitive Landscape

CompanyLead AssetStageMarket Cap
Apogee (APGE)APG777 (IL-13)Phase 2$3.7B
Regeneron/SanofiDupixent (IL-4/IL-13)Approved$100B+
Eli LillyLebrikizumab (IL-13)Approved$700B+
GaldermaNemolizumab (IL-31)Approved$15B
AnaptysBioRosnilimab (IL-13)Phase 2b$1.1B

Apogee competes in a crowded but massive market. Dupixent's $10B+ sales validate demand, but also attract competition. Apogee's best-case scenario is demonstrating superior efficacy, safety, or convenience that justifies either partnership with big pharma or successful commercialization as an independent company. The $3.7B valuation assumes successful Phase 2/3 execution—not commercial success yet.

Who Is This Stock Suitable For?

Perfect For

  • ✓Aggressive biotech investors with 3-5 year horizons and 100% loss tolerance
  • ✓Thematic investors betting on inflammatory disease therapies megatrend
  • ✓Portfolio speculators allocating <5% to high-risk/high-reward clinical bets
  • ✓Experienced biotech traders who understand clinical trial risk and timing

Less Suitable For

  • ✗Income investors (no dividend, pre-revenue)
  • ✗Risk-averse investors or retirees who can't afford losses
  • ✗Value investors seeking profitable companies with cash flows
  • ✗Buy-and-hold investors uncomfortable with 50%+ intra-year volatility

Investment Thesis

Apogee Therapeutics exemplifies classic biotech risk/reward. The company has credible science (targeting validated pathways), experienced management (Michael Henderson previously at Merck and Regeneron), strong backing ($700M+ raised), and unanimous analyst support (11 Buy ratings). Phase 2 data from APG777 will determine whether APGE is worth $6B+ (successful differentiation vs. Dupixent) or $1.5B (me-too drug with limited upside). Analyst consensus at $96 (53% upside) reflects optimism tempered by execution risk.

The bull case is straightforward: APG777 demonstrates superiority in Phase 2, Apogee advances to Phase 3 successfully, and either Big Pharma acquires the company at $8-10B (140%+ gain) or Apogee commercializes independently generating $2B+ peak sales. At $62.96, the market prices in ~60% probability of success—reasonable given validated mechanism and strong preclinical data. The bear case is equally clear: clinical trial failure sends the stock back to $20-30, cash burn forces dilutive capital raise, or competitive differentiation fails to materialize despite positive data.

Conclusion

APGE merits a SPECULATIVE BUY for aggressive biotech portfolios allocating 3-5% to clinical-stage plays. The unanimous analyst support (11 Buy ratings, zero Holds/Sells), strong cash position ($700M runway), and near-term catalysts (Phase 2 data Q1 2026) create compelling asymmetry. However, this is explicitly NOT for conservative investors: zero revenue, -$270M EBITDA, and binary clinical outcomes make 50%+ volatility inevitable. Size positions assuming 40% probability of total loss, with 2-3x upside if APG777 succeeds.
Bull Case
$140 (122% upside)
Base Case
$96 (53% upside)
Bear Case
$25 (60% downside)

Stay Ahead of the Market with Apogee Therapeutics, Inc. Alerts

Set up price alerts for Apogee Therapeutics, Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.